Libtayo — Revenue
Regeneron Pharmaceuticals Libtayo — Revenue increased by 3.0% to $438.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 53.7%, from $285.10M to $438.20M. Over 3 years (FY 2022 to FY 2025), Libtayo — Revenue shows an upward trend with a 48.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase in revenue indicates growing market share, successful clinical adoption, or expansion into new oncology indications, while a decrease may signal increased competition from other checkpoint inhibitors or market saturation.
Detailed definition
This metric represents the total net product sales generated from the commercialization of Libtayo, an anti-PD-1 monoclo...
Peer comparison
Comparable to oncology-focused product revenue lines at other biopharmaceutical companies, such as sales of Keytruda or Opdivo, where market penetration in immuno-oncology is a key performance indicator.
regn_segment_libtayo_revenuesHistorical Data
| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.40M | $78.90M | $90.90M | $125.70M | $152.00M | $176.90M | $210.00M | $232.40M | $243.80M | $263.90M | $297.40M | $288.60M | $366.90M | $285.10M | $376.50M | $365.20M | $425.40M | $438.20M |
| QoQ Change | — | +0.6% | +15.2% | +38.3% | +20.9% | +16.4% | +18.7% | +10.7% | +4.9% | +8.2% | +12.7% | -3.0% | +27.1% | -22.3% | +32.1% | -3.0% | +16.5% | +3.0% |
| YoY Change | — | — | — | +60.3% | — | +124.2% | +131.0% | +84.9% | +60.4% | +49.2% | +41.6% | +24.2% | +50.5% | +8.0% | +26.6% | +26.5% | +15.9% | +53.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's libtayo — revenue?
- Regeneron Pharmaceuticals (REGN) reported libtayo — revenue of $438.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's libtayo — revenue changed year-over-year?
- Regeneron Pharmaceuticals's libtayo — revenue increased by 53.7% year-over-year, from $285.10M to $438.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's libtayo — revenue?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's libtayo — revenue has grown at a 48.1% compound annual growth rate (CAGR), from $447.50M to $1.45B.
- What does libtayo — revenue mean?
- The total net revenue generated from the sale of the oncology drug Libtayo.